Reach Us 441235425476


Rituximab-induced Bronchiolitis Obliterans Treated with Intravenous Immunoglobulin

Bronchiolitis Obliterans (BO) is a clinical syndrome associated with dyspnea and airflow limitation due to fibroproliferative thickening of the bronchiolar walls which can progress to the complete obliteration. Varying etiologies have been known to incite this process, with no definitive course of treatment that has demonstrated consistent clinical benefit. Rituximab is a monoclonal antibody with antineoplastic properties, of which bronchiolitis obliterans has been described as a complication of therapy. This is a case describing Intravenous Immunoglobulin (IVIG) as therapy for bronchiolitis obliterans refractory to systemic steroids.

Author(s): Christopher Halpin, Erica McGovern and Jeffrey Hoag

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Recommended Conferences
Flyer image